Fulgent Genetics, Inc. (FLGT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '21: 227.9M Q4 '21: 251.7M Q1 '22: 320.3M Q2 '22: 125.3M Q3 '22: 105.7M Q4 '22: 67.7M Q1 '23: 66.2M Q2 '23: 67.9M Q3 '23: 84.7M Q4 '23: 70.5M Q1 '24: 64.5M Q2 '24: 71M Q3 '24: 71.7M Q4 '24: 76.2M Q1 '25: 73.5M Q2 '25: 81.8M Q3 '25: 84.1M Q4 '25: 83.3M Q1 '26: 71.1M Q2 '26: 85.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 90M 180M 270M Q3 '21: 184.4M Q4 '21: 189.5M Q1 '22: 242.5M Q2 '22: 65.3M Q3 '22: 46.1M Q4 '22: 13M Q1 '23: 18.8M Q2 '23: 20.6M Q3 '23: 39.8M Q4 '23: 25.2M Q1 '24: 22.1M Q2 '24: 26.5M Q3 '24: 26.8M Q4 '24: 31.8M Q1 '25: 28.3M Q2 '25: 34.4M Q3 '25: 35.5M Q4 '25: 32.6M Q1 '26: 21.5M Q2 '26: 25.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: 159.3M Q4 '21: 150.9M Q1 '22: 201.9M Q2 '22: 12.8M Q3 '22: 352K Q4 '22: -36.6M Q1 '23: -24.8M Q2 '23: -19.8M Q3 '23: 214K Q4 '23: -151.1M Q1 '24: -21.8M Q2 '24: -18.9M Q3 '24: -17.1M Q4 '24: -16.1M Q1 '25: -19.8M Q2 '25: -19.7M Q3 '25: -15.3M Q4 '25: -36.2M Q1 '26: -34.6M Q2 '26: -36.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: 122.5M Q4 '21: 104.3M Q1 '22: 154M Q2 '22: 11.5M Q3 '22: 1.7M Q4 '22: -23.8M Q1 '23: -15.3M Q2 '23: -11.2M Q3 '23: -13.1M Q4 '23: -128.1M Q1 '24: -13.5M Q2 '24: -8.7M Q3 '24: -14.6M Q4 '24: -5.9M Q1 '25: -11.5M Q2 '25: -19M Q3 '25: -6.6M Q4 '25: -23.4M Q1 '26: -24.8M Q2 '26: -29.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 30M 60M 90M Q3 '21: 43.5M Q4 '21: 62.1M Q1 '22: 77.7M Q2 '22: 60.1M Q3 '22: 59.6M Q4 '22: 54.7M Q1 '23: 47.4M Q2 '23: 47.3M Q3 '23: 44.8M Q4 '23: 45.3M Q1 '24: 42.4M Q2 '24: 44.5M Q3 '24: 45M Q4 '24: 44.4M Q1 '25: 45.1M Q2 '25: 47.4M Q3 '25: 48.6M Q4 '25: 50.8M Q1 '26: 49.6M Q2 '26: 59.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-140M -70M 0 70M 140M 210M Q3 '21: 152.2M Q4 '21: 77.1M Q1 '22: 188.4M Q2 '22: 11.1M Q3 '22: 20.8M Q4 '22: 33.2M Q1 '23: -7.9M Q2 '23: 9.7M Q3 '23: 10.2M Q4 '23: 14.9M Q1 '24: 7.3M Q2 '24: 4.3M Q3 '24: -15.5M Q4 '24: 25M Q1 '25: -4.4M Q2 '25: -30.2M Q3 '25: 11.1M Q4 '25: -78.1M Q1 '26: 7.1M Q2 '26: -23.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-140M -70M 0 70M 140M 210M Q3 '21: 148.8M Q4 '21: 71.1M Q1 '22: 183.1M Q2 '22: 7.9M Q3 '22: 15.3M Q4 '22: 28.5M Q1 '23: -9.9M Q2 '23: -2.4M Q3 '23: 5.3M Q4 '23: 11.8M Q1 '24: 3.2M Q2 '24: -8.7M Q3 '24: -35M Q4 '24: 21.2M Q1 '25: -9.1M Q2 '25: -37M Q3 '25: 5.1M Q4 '25: -83.1M Q1 '26: 1.9M Q2 '26: -27.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 21.6M Q2 '20: 22.9M Q3 '20: 23.5M Q1 '21: 30.8M Q2 '21: 30.8M Q3 '21: 31.2M Q1 '22: 31.2M Q2 '22: 31.2M Q3 '22: 30.9M Q1 '23: 29.5M Q2 '23: 29.8M Q3 '23: 30M Q1 '24: 29.8M Q2 '24: 30.1M Q3 '24: 30.4M Q1 '25: 30.8M Q2 '25: 30.5M Q3 '25: 30.7M Q1 '26: 30.9M Q2 '26: 28M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q3 '17: 0.00 Q4 '17: -0.14 Q1 '18: -0.26 Q2 '18: -0.32 Q3 '18: -0.29 Q4 '18: -0.31 Q3 '17 Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.